세계의 항체 치료제 시장 : 형태별, 질환 영역별, 투여 경로별, 최종사용자별, 지역별, 경쟁 상황 - 분석 및 예측(2024-2033년)

Global Antibody Therapeutic Market: Focus on Format, Disease Area, Route of Administration, End Users, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033

US $ 2,475 ￦ 3,655,000

PDF and Excel (1-3 User License)

PDF 및 Excel 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 3,825 ￦ 5,649,000

PDF and Excel (Global License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 항체 치료제 시장은 바이오의약품 및 생명과학 분야에서 매우 중요한 역할을 담당하고 있으며, 의료 및 연구 분야에서 다양한 용도로 사용되는 항체의 생산, 발전 및 상용화에 전념하고 있습니다.

이러한 항체(면역글로불린)는 면역계에서 생성되는 필수 단백질로 유해한 병원체, 독소 및 이물질을 식별하고 중화시키는 데 매우 중요합니다. 시장에서 항체는 진단, 치료, 연구, 질병 탐지 및 치료, 실험실 실험 및 의약품 개발 등 다양한 목적으로 생산, 변형 및 응용되고 있습니다.

세계 항체 치료제 시장의 확대는 몇 가지 주요 요인에 의해 촉진되었습니다. 주로 만성 질환의 유병률 증가와 표적 치료에 대한 수요 증가로 인해 혁신적인 치료법에 대한 탐색이 강화되고 있습니다.

본 보고서는 세계 항체 치료제 시장을 조사하여 시장 개요와 함께 형태별, 질환 영역별, 투여 경로별, 최종사용자별, 지역별 동향, 시장 진입 기업 개요 등을 제공합니다.

목차

주요 요약

제1장 시장

• 동향 : 현재 및 향후의 영향 평가
• 공급망 개요
• 연구개발 리뷰
• 규제 상황
• 주요 세계적 사건의 영향 분석 - COVID-19
• 시장 역학 개요

제2장 용도

• 용도 세분화
• 용도 개요
• 세계의 항체 치료제 시장(질환 영역별)
• 세계의 항체 치료제 시장(투여 경로별)
• 세계의 항체 치료제 시장(최종사용자별)

제3장 제품

• 제품 세분화
• 제품 개요
• 세계의 항체 치료제 시장
• 세계의 항체 치료제 시장(형태별)

제4장 지역

• 지역별 개요
• 성장 촉진요인과 억제요인
• 북미
• 유럽
• 아시아태평양
• 기타 지역

제5장 시장 - 경쟁 벤치마킹과 기업 개요

• 향후 유력 기업
• 지리적 평가
  • Hoffmann-La Roche Ltd.
  • AbbVie, Inc
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Regeneron Pharmaceuticals Inc.
  • Novartis AG
  • AstraZeneca
  • Eli Lilly and Company
  • GlaxoSmithKline plc.
  • Takeda Pharmaceutical Company Ltd.
  • Abcam Plc.
  • Thermo Fisher Scientific, Inc
  • Cell Signaling Technology

제6장 조사 방법

ksm

영문 목차

영문목차

“Global Antibody Therapeutic Market Poised for Remarkable Growth.”

The global antibody therapeutic market occupies a pivotal role within the biopharmaceutical and life sciences sectors, dedicated to the manufacturing, advancement, and commercialization of antibodies with diverse applications in medical and research domains. These antibodies, or immunoglobulins, are essential proteins generated by the immune system, crucial for identifying and neutralizing harmful pathogens, toxins, and foreign substances. Within the market context, antibodies are produced, modified, and applied for a spectrum of purposes, encompassing diagnostics, therapeutics, and research endeavors, spanning disease detection and treatment to laboratory experiments and pharmaceutical development.

The expansion of the global antibody therapeutic markets was propelled by several influential factors. Primarily, the rising prevalence of chronic diseases and the escalating demand for targeted therapies have intensified the quest for innovative treatment modalities.

Market Segmentation:

Segmentation 1: by Disease Area

• Autoimmune and Inflammatory Disease
• Oncology
• Haematology
• Infectious Disease
• Osteology
• Immunology
• Neurology
• Others Disease Area

Segmentation 2: by Route of Administration

• Intravenous
• Subcutaneous
• Others Route of Administration

Segmentation 3: by End-User

• Hospitals
• Long term Care Facilities
• Others End-User

Segmentation 4: by Format

• Monoclonal Antibodies
• Polyclonal Antibodies
• Antibody Fragments
• Bispecific Antibodies
• Others Novel Antibody Therapies

Segmentation 5: by Region

• North America
• Europe
• Asia-Pacific
• Rest-of-the-World

Key Questions Answered:

• What are the growth opportunities for new entrants in the global antibody therapeutic sector?
• Who are the primary players operating within the global antibody therapeutics market?
• What key strategies are likely to be embraced by participants aiming to expand their share in the global antibody therapeutic industry?
• How is the competitive landscape shaping up in the global antibody therapeutics market?
• What emerging trends might impact the growth of the global antibody therapeutics market?
• Which product type segment is anticipated to demonstrate a substantial CAGR in the future?
• Which application segment is poised to capture a significant share in the global antibody therapeutic industry?
• Which region presents lucrative opportunities for manufacturers in the global antibody therapeutics market?

Table of Contents

Executive Summary

1. Markets

• 1.1. Trends: Current and Future Impact Assessment
  • 1.1.1. Sample Text
  • 1.1.2. Trend 1
  • 1.1.3. Trend 2
  • 1.1.4. Trend 3
• 1.2. Supply chain Overview
  • 1.2.1. Value Chain Analysis
  • 1.2.2. Market Map
• 1.3. Research and Development Review
  • 1.3.1. Patent Filing Trend (by Country, Company)
• 1.4. Regulatory Landscape
• 1.5. Impact Analysis for Key Global Events- COVID-19
• 1.6. Market Dynamics Overview
  • 1.6.1. Market Drivers
  • 1.6.2. Market Restraints
  • 1.6.3. Market Opportunities

2. Application

• 2.1. Application Segmentation
• 2.2. Application Summary
• 2.3. Global Antibody Therapeutic Market (By Disease Area)
  • 2.3.1. Autoimmune and Inflammatory Disease
  • 2.3.2. Oncology
  • 2.3.3. Haematology
  • 2.3.4. Infectious Disease
  • 2.3.5. Osteology
  • 2.3.6. Immunology
  • 2.3.7. Neurology
  • 2.3.8. Others Disease Area
• 2.4. Global Antibody Therapeutic Market (By Route of Administration)
  • 2.4.1. Intravenous
  • 2.4.2. Subcutaneous
  • 2.4.3. Others Route of Administration
• 2.5. Global Antibody Therapeutic Market (By End-User)
  • 2.5.1. Hospitals
  • 2.5.2. Long term Care Facilities
  • 2.5.3. Others End-User

3. Products

• 3.1. Product Segmentation
• 3.2. Product Summary
• 3.3. Global Antibody Therapeutic Market
  • 3.3.1. Market Overview
    • 3.3.1.1. Analyst View
• 3.4. Global Antibody Therapeutic Market (By Format)
  • 3.4.1. Monoclonal Antibodies
  • 3.4.2. Polyclonal Antibodies
  • 3.4.3. Antibody Fragments
  • 3.4.4. Bispecific Antibodies
  • 3.4.5. Others Novel Antibody Therapies

4. Regions

• 4.1. Regional Summary
• 4.2. Drivers and Restraints
• 4.3. North America
  • 4.3.1. Regional Overview
  • 4.3.2. Driving Factors for Market Growth
  • 4.3.3. Factors Challenging the Market
  • 4.3.4. Application
  • 4.3.5. Product
  • 4.3.6. U.S.
  • 4.3.7. U.S. Antibody Therapeutic Market by Application
  • 4.3.8. Canada
  • 4.3.9. Canada Antibody Therapeutic Market by Application
• 4.4. Europe
  • 4.4.1. Regional Overview
  • 4.4.2. Driving Factors for Market Growth
  • 4.4.3. Factors Challenging the Market
  • 4.4.4. Application
  • 4.4.5. Product
  • 4.4.6. Germany
  • 4.4.7. Germany Antibody Therapeutic Market by Application
  • 4.4.8. U.K.
  • 4.4.9. U.K. Antibody Therapeutic Market by Application
  • 4.4.10. France
  • 4.4.11. France Antibody Therapeutic Market by Application
  • 4.4.12. Rest of Europe
  • 4.4.13. Rest of Europe Antibody Therapeutic Market by Application
• 4.5. Asia Pacific
  • 4.5.1. Regional Overview
  • 4.5.2. Driving Factors for Market Growth
  • 4.5.3. Factors Challenging the Market
  • 4.5.4. Application
  • 4.5.5. Product
  • 4.5.6. China
  • 4.5.7. China Antibody Therapeutic Market by Application
  • 4.5.8. Japan
  • 4.5.9. Japan Antibody Therapeutic Market by Application
  • 4.5.10. India
  • 4.5.11. India Antibody Therapeutic Market by Application
  • 4.5.12. Rest-of-Asia-Pacific
  • 4.5.13. Rest-of-Asia-Pacific Antibody Therapeutic Market by Application
• 4.6. Rest-of-the-World (RoW)
  • 4.6.1. Regional Overview
  • 4.6.2. Driving Factors for Market Growth
  • 4.6.3. Factors Challenging the Market
  • 4.6.4. Application
  • 4.6.5. Product
  • 4.6.6. Latin America
  • 4.6.7. Latin America Antibody Therapeutic Market by Application
  • 4.6.8. The Middle East and Africa
  • 4.6.9. The Middle East and Africa Antibody Therapeutic Market by Application

5. Markets - Competitive Benchmarking & Company Profiles

• 5.1. Next Frontiers…..
• 5.2. Geographic Assessment
  • 5.2.1. Hoffmann-La Roche Ltd.
    • 5.2.1.1. Overview
    • 5.2.1.2. Top Products / Product Portfolio
    • 5.2.1.3. Top Competitors
    • 5.2.1.4. Target Customers
    • 5.2.1.5. Key Personnel
    • 5.2.1.6. Analyst View
    • 5.2.1.7. Market Share
  • 5.2.2. AbbVie, Inc
    • 5.2.2.1. Overview
    • 5.2.2.2. Top Products / Product Portfolio
    • 5.2.2.3. Top Competitors
    • 5.2.2.4. Target Customers
    • 5.2.2.5. Key Personnel
    • 5.2.2.6. Analyst View
    • 5.2.2.7. Market Share
  • 5.2.3. Amgen Inc.
    • 5.2.3.1. Overview
    • 5.2.3.2. Top Products / Product Portfolio
    • 5.2.3.3. Top Competitors
    • 5.2.3.4. Target Customers
    • 5.2.3.5. Key Personnel
    • 5.2.3.6. Analyst View
    • 5.2.3.7. Market Share
  • 5.2.4. Bristol-Myers Squibb Company
    • 5.2.4.1. Overview
    • 5.2.4.2. Top Products / Product Portfolio
    • 5.2.4.3. Top Competitors
    • 5.2.4.4. Target Customers
    • 5.2.4.5. Key Personnel
    • 5.2.4.6. Analyst View
    • 5.2.4.7. Market Share
  • 5.2.5. Johnson & Johnson Services, Inc.
    • 5.2.5.1. Overview
    • 5.2.5.2. Top Products / Product Portfolio
    • 5.2.5.3. Top Competitors
    • 5.2.5.4. Target Customers
    • 5.2.5.5. Key Personnel
    • 5.2.5.6. Analyst View
    • 5.2.5.7. Market Share
  • 5.2.6. Merck & Co., Inc.
    • 5.2.6.1. Overview
    • 5.2.6.2. Top Products / Product Portfolio
    • 5.2.6.3. Top Competitors
    • 5.2.6.4. Target Customers
    • 5.2.6.5. Key Personnel
    • 5.2.6.6. Analyst View
    • 5.2.6.7. Market Share
  • 5.2.7. Regeneron Pharmaceuticals Inc.
    • 5.2.7.1. Overview
    • 5.2.7.2. Top Products / Product Portfolio
    • 5.2.7.3. Top Competitors
    • 5.2.7.4. Target Customers
    • 5.2.7.5. Key Personnel
    • 5.2.7.6. Analyst View
    • 5.2.7.7. Market Share
  • 5.2.8. Novartis AG
    • 5.2.8.1. Overview
    • 5.2.8.2. Top Products / Product Portfolio
    • 5.2.8.3. Top Competitors
    • 5.2.8.4. Target Customers
    • 5.2.8.5. Key Personnel
    • 5.2.8.6. Analyst View
    • 5.2.8.7. Market Share
  • 5.2.9. AstraZeneca
    • 5.2.9.1. Overview
    • 5.2.9.2. Top Products / Product Portfolio
    • 5.2.9.3. Top Competitors
    • 5.2.9.4. Target Customers
    • 5.2.9.5. Key Personnel
    • 5.2.9.6. Analyst View
    • 5.2.9.7. Market Share
  • 5.2.10. Eli Lilly and Company
    • 5.2.10.1. Overview
    • 5.2.10.2. Top Products / Product Portfolio
    • 5.2.10.3. Top Competitors
    • 5.2.10.4. Target Customers
    • 5.2.10.5. Key Personnel
    • 5.2.10.6. Analyst View
    • 5.2.10.7. Market Share
  • 5.2.11. GlaxoSmithKline plc.
    • 5.2.11.1. Overview
    • 5.2.11.2. Top Products / Product Portfolio
    • 5.2.11.3. Top Competitors
    • 5.2.11.4. Target Customers
    • 5.2.11.5. Key Personnel
    • 5.2.11.6. Analyst View
    • 5.2.11.7. Market Share
  • 5.2.12. Takeda Pharmaceutical Company Ltd.
    • 5.2.12.1. Overview
    • 5.2.12.2. Top Products / Product Portfolio
    • 5.2.12.3. Top Competitors
    • 5.2.12.4. Target Customers
    • 5.2.12.5. Key Personnel
    • 5.2.12.6. Analyst View
    • 5.2.12.7. Market Share
  • 5.2.13. Abcam Plc.
    • 5.2.13.1. Overview
    • 5.2.13.2. Top Products / Product Portfolio
    • 5.2.13.3. Top Competitors
    • 5.2.13.4. Target Customers
    • 5.2.13.5. Key Personnel
    • 5.2.13.6. Analyst View
    • 5.2.13.7. Market Share
  • 5.2.14. Thermo Fisher Scientific, Inc
    • 5.2.14.1. Overview
    • 5.2.14.2. Top Products / Product Portfolio
    • 5.2.14.3. Top Competitors
    • 5.2.14.4. Target Customers
    • 5.2.14.5. Key Personnel
    • 5.2.14.6. Analyst View
    • 5.2.14.7. Market Share
  • 5.2.15. Cell Signaling Technology
    • 5.2.15.1. Overview
    • 5.2.15.2. Top Products / Product Portfolio
    • 5.2.15.3. Top Competitors
    • 5.2.15.4. Target Customers
    • 5.2.15.5. Key Personnel
    • 5.2.15.6. Analyst View
    • 5.2.15.7. Market Share

6. Research Methodology

• 6.1. Data Sources
  • 6.1.1. Primary Data Sources
  • 6.1.2. Secondary Data Sources
  • 6.1.3. Data Triangulation
• 6.2. Market Estimation and Forecast

관련자료